Reuters logo
BRIEF-Miragen Therapeutics receives orphan-drug designation for MRG-106
March 31, 2017 / 11:33 AM / 7 months ago

BRIEF-Miragen Therapeutics receives orphan-drug designation for MRG-106

March 31 (Reuters) - Miragen Therapeutics Inc:

* Miragen Therapeutics receives orphan-drug designation for MRG-106 for the treatment of mycosis fungoides Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below